Founding Team
Our founders bring deep expertise in cutting-edge oncology research and successful gene therapy product development and company formation. We’ve combined this know-how to change the paradigm in cancer treatment outcomes with AAV-delivered T-cell Immunotherapy.
Read Dr. Cripe’s landmark publication in Scientific Advances describing a single-dose cancer immunotherapy via gene transfer that formed the foundation for Vironexis and our TransJoin AAV Gene Therapy Platform.